ETF PROAI

IHEvsSPMD

iShares U.S. Pharmaceuticals ETF against SPDR Portfolio S&P 400 Mid Cap ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IHE 130SPMD 112Oct 25Oct 26GROWTH OF $100
Head to head
IHESPMD
Expense ratio0.40%0.030%
Assets$1.6B$18.1B
Net flow, 1 month+$25M+$190M
Net flow, 1 year+$795M+$2.1B
Return, YTD+16.3%+11.0%
Return, 1 year+30.5%+11.6%
Avg daily volume177K1.6M
Holdings38401
ListedMay 1, 2006Nov 8, 2005
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.